Form 4: Enliven CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics CEO Samuel Kintz sold common stock shares totaling $219,896 under a pre-arranged 10b5-1 trading plan.
Summary
- Samuel Kintz, President and CEO, and a Director of Enliven Therapeutics, Inc. (ELVN), reported sales of company common stock.
- On August 18, 2025, 10,393 shares were sold at a weighted average price of $20.0237 per share, totaling approximately $208,096.
- On August 19, 2025, an additional 590 shares were sold at $20.00 per share, totaling $11,800.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
- Following these sales, 929,409 shares are beneficially owned indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which Samuel Kintz serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's insider selling, it was conducted under a pre-arranged 10b5-1 plan, which suggests it's not based on new, negative information about the company. It's a routine liquidity event for the insider.
Negatives
- Insider selling, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May view the reduction in insider ownership as a slight negative, though mitigated by the 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 2019-03-30 | Date of The Kintz & Egan Trust. |
| 2024-11-15 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-08-18 | Transaction date for the sale of 10,393 shares of common stock. |
| 2025-08-19 | Transaction date for the sale of 590 shares of common stock. |
| 2025-08-20 | Date the Form 4 was signed. |
Keywords
Enliven Therapeutics, ELVN, Samuel Kintz, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.